VEGFA and metastatic colorectal cancer: Fruquintinib, also known as HMPL-013, is typically used as a third-line therapy for metastatic colorectal cancer; its mechanism specifically involves targeting the tyrosine kinases of 3 different receptors of VEGF (6).